Dendreon Plunges on Provenge Revenue Forecast Withdrawal

1,538 views · Published 4 August 2011 · 2:45 · Indexed 30 October 2026

Channel: Bloomberg Originals · 2011 · Entertainment

Watch on YouTube

Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue estimate and said sales of the medicine didn't meet projections. Shannon Pettypiece reports on Bloomberg Television's "In the Loop." (Source: Bloomberg)

More from this channel